Your email has been successfully added to our mailing list.

×
0.00985221674876844 0.0394088669950739 0.0344827586206896 0.00985221674876844 -0.0591133004926108 -0.0640394088669951 -0.164532019704433 -0.3064039408867
Stock impact report

Verona Pharma shares shoot higher on Phase 2 trial of respiratory drug [MarketWatch]

Verona Pharma plc - American Depositary Shares (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
Company Research Source: MarketWatch
Verona Pharma shares shoot higher on Phase 2 trial of respiratory drug Verona Pharma VRP, +68.97% VRNA, +5.67% surged 69% in London trade as the biopharma said a Phase 2b study evaluating a drug for chronic obstructive pulmonary disease met its primary endpoint of improved lung function. The study of nebulized ensifentrine as an add-on treatment to tiotropium found a statistically significant and clinically meaningful improvement in lung function at week 4. Show less Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for VRNA alerts
Opt-in for
VRNA alerts

from News Quantified
Opt-in for
VRNA alerts

from News Quantified